Quanterix, a privately held developer of medical diagnostics technology in Cambridge, MA, has raised $15 million in a Series A financing, according to VentureWire. Arch Venture Partners, Bain Capital, and Flagship Ventures participated in the financing. Tufts University researcher David Walt, a founder of San Diego-based Illumina (NASDAQ: [[ticker:ILMN]]) is a co-founder of Quanterix. The company’s technology is used to identify single molecules in human blood, which escape detection from standard Elisa diagnostic tests, according to the company’s web site.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
